Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P693

Thiopurine-induced leucopenia and hair loss were inevitable in Japanese IBD patients homozygous for NUDT15 R139C : a case series

Authors:

T. Naito*, Y. Kakuta, M. Onodera, T. Kimura, M. Kuroha, H. Shiga, K. Endo, K. Negoro, Y. Kinouchi, T. Shimosegawa

Tohoku University Graduate School of Medicine, Gastroenterology, Sendai, Japan

P694. Chronic cigarette smoke exposure alters the murine gut microbiome
Authors:

L. Allais1, F.-M. Kerckhof2, S. Verschuere1, K. Bracke3, R. De Smet1, D. Laukens4, M. Devos4, N. Boon2, G. Brusselle3, T. Van de Wiele2, C. Cuvelier1, 1Ghent University, Pathology, Faculty of Medicine & Health Sciences, Ghent, Belgium, 2Ghent University, Laboratory of Microbial Ecology and Technology, Faculty of Bioscience Engineering, Ghent, Belgium, 3Ghent University, Laboratory for Translational Research in Obstructive Pulmonary diseases, Department of Respiratory Medicine, Faculty of Medicine & Health Sciences, Ghent, Belgium, 4Ghent University, Department of Gastroenterology, Faculty of Medicine & Health Sciences, Ghent, Belgium

P694

A functional variant of SLC26A3 in association with Ulcerative Colitis down regulates SLC26A3 expression

Authors:

A. Hirano*1, 2, J. Umeno1, K. Asano1, M. Esaki1, T. Matsumoto3

1Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 2Yamaguchi Red Cross Hospital, Department of internal medicine, Yamaguchi, Japan, 3Iwate Medical University, Division of Gastroenterology, Department of Internal Medicine, Morioka, Japan

P695. Efficacy of vaccination against hepatitis A and B in inflammatory bowel disease patients: preliminary results
Authors:

K. Karmiris1, E. Voudoukis1, G.A. Paspatis1, 1Venizeleio General Hospital, Gastroenterology, Heraklion, Crete, Greece

P695

A mutation in CTLA4 associated with early-onset Crohn's disease and autoimmunity

Authors:

S. Zeissig*1, B.-S. Petersen2, M. Tomczak3, E. Melum4, E. Huc-Claustre1, S. Dougan3, J.K. Laerdahl5, B. Stade2, M. Forster2, S. Schreiber1, D. Weir6, A.M. Leichtner6, A. Franke2, R.S. Blumberg3

1Kiel University, Department of Internal Medicine I, Kiel, Germany, 2Christian-Albrechts-University Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, 3Brigham and Women's Hospital, Division of Gastroenterology, Hepatology, and Endoscopy, Boston, United States, 4Oslo University Hospital, Norwegian PSC Research Center, Oslo, Norway, 5Oslo University Hospital, Department of Microbiology, Oslo, Norway, 6Boston Children’s Hospital, Division of Gastroenterology, Hepatology and Nutrition, Boston, United States

P696. Terminal restriction fragment length polymorphism (TRFLP) analysis of mucosa-associated microbiota of patients with ulcerative colitis in southwest China
Authors:

W. Ran1, O. Qin1, 1Sichuan University, The Department of Gastroenterology of West China hospital of Sichuan University, Chendu, China

P696

HLA-DRB1 is involved in the development of antibodies to infliximab in Inflammatory Bowel Disease

Authors:

T. Billiet*1, N. Vande Casteele2, T. Van Stappen2, I. Cleynen1, V. Ballet3, K. Claes1, F. Princen4, S. Singh4, A. Gils2, M. Ferrante3, G. Van Assche3, S. Vermeire3

1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 2KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium, 3University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 4Prometheus Laboratories, Department of Research and Development, San Diego, United States

P697. Candida albicans colonization and anti-glycan antibodies in active and quiescent Crohn's disease
Authors:

R. Gerard1, B. Sendid2, A. Techy1, G. Vernier-Massouille1, T. Jouault2, N. Francois2, J.-F. Colombel1, D. Poulain2, 1Université Lille Nord de France, Clinique des maladies de l'appareil digestif, Hôpital Huriez, Inserm U995, CHRU de Lille, Gastroenterology, Lille, France, 2Université Lille Nord de France, Laboratoire de Parasitologie Mycologie, Inserm U995, CHRU de Lille, Parasitology-Mycology, Lille, France

P697

Human-leukocyte antigen type is associated with duration on infliximab therapy in patients with antibodies to infliximab

Authors:

T. Billiet*1, T. Van Stappen2, N. Vande Casteele2, I. Cleynen1, V. Ballet3, K. Claes1, F. Princen4, S. Singh4, A. Gils2, M. Ferrante3, G. Van Assche3, S. Vermeire3

1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 2KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium, 3University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 4Prometheus Laboratories, Department of Research and Development, San Diego, United States

P698. Characterization of the tissue-associated microbiome in active and inactive IBD
Authors:

A. Tyler1, J. Stempak1, D. Gevers2, C. Huttenhower3, M. Silverberg1, 1Mount Sinai Hospital, Toronto, Canada, 2The Broad Institute of MIT and Harvard, Boston, United States, 3Harvard University, School of Public Health, Boston, United States

P698

Methylomic profiling in Inflammatory Bowel Disease: New insights into disease pathogenesis and activity

Authors:

E. McDermott*1, E. Ryan1, M. Tosetto1, J. Burrage2, J. Mill2, G. Doherty1, G. Cullen1, H. Mulcahy1, T. Murphy2

1St. Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 2University of Exeter , Medical School, Exeter, United Kingdom

P699. Temporal bacterial community dynamics vary among ulcerative colitis patients after faecal microbiota transplantation
Authors:

S. Angelberger1, W. Reinisch1, A. Makristathis2, C. Lichtenberger1, C. Dejaco1, P. Papay1, G. Novacek1, M. Trauner1, A. Loy3, D. Berry3, 1Medical University of Vienna, Internal Medicine III, Vienna, Austria, 2Medical University of Vienna, Clinical Microbiology, Vienna, Austria, 3University of Vienna, Faculty of Life Science, Microbial Ecology, Vienna, Austria

P699

Genetic and clinical characterization of 56 multiple-affected IBD families

Authors:

A. Settesoldi*1, M. Vancamelbeke2, T. Billiet2, V. Ballet3, S. Singh4, S. Lockton4, F. Princen4, G. Van Assche3, P. Rutgeerts3, S. Vermeire3, I. Cleynen2

1AOU Careggi, Gastroenterology, Florence, Italy, 2Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 3UZ Leuven, Gastroenterology, Leuven, Belgium, 4Prometheus Therapeutics & diagnostics, Prometheus Laboratories Inc, San Diego, California, United States

P700. Evaluation of location-specific, tissue-associated microbiota in the ileal pouch, terminal ileum and colon in inflammatory bowel disease (IBD)
Authors:

A. Tyler1, C. Huttenhower2, D. Gevers3, M. Silverberg1, 1Mount Sinai Hospital, Toronto, Canada, 2Harvard University, School of Public Health, Boston, United States, 3The Broad Institute of MIT and Harvard, Boston, United States

P700

Genetic polymorphisms in IBD determine response to treatment

Authors:

V. Nuij*, M. Peppelenbosch, C.J. Van der Woude, G. Fuhler

ErasmusMC University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands

P701. Cytomegalovirus-specific T-cell response is conserved in IBD patients
Authors:

R. Caccaro1, A. Saldan2, D. Abate2, M. Martinato1, R. D'Incà1, G. Palù2, G.C. Sturniolo1, 1University of Padova, Department of Surgical Oncological and Gastroenterological Sciences, Padova, Italy, 2University of Padova, Department of Molecular Medicine, Padova, Italy

P701

The contribution of genetics in differentiating inflammatory bowel disease type unclassified

Authors:

T. Billiet*1, I. Cleynen1, V. Ballet2, K. Claes1, F. Princen3, S. Singh3, M. Ferrante2, G. Van Assche2, S. Vermeire2

1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 2University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3Prometheus Laboratories, Department of Research and Development, San Diego, United States

P702. Clinical significance of cytomegalovirus (CMV) infection in inflammatory bowel disease
Authors:

G. Inserra1, M. Mendolaro1, S. Siringo2, G. Scalia3, L. Samperi1, M.C. Conti Bellocchi1, R. Catanzaro1, 1A.O.U. Policlinico-Vittorio Emanuele, U.O. Medicina interna, Catania, Italy, 2ARNAS Garibaldi, Gastroenterogia, Catania, Italy, 3A.O.U. Policlinico-Vittorio Emanuele, Laboratorio di Virologia Clinica, Catania, Italy

P702

Influences of XDH genotype on thiopurine-induced leukopenia in Korean patients with Crohn's disease determined by gene-gene interactions

Authors:

P. Soo-kyung*1, Y. Suk-Kyun2, H. Myunghee3, B. Jiwon3, C. Hyunchul3, J. Yusun3, Y. Byong Duk2, K. Kyung-Jo2, P. Sang Hyoung2, Y. Dong-Hoon2, C. Jae Myung4, S. Kyuyoung3

1SoonChunHyang University Bucheon Hospital, Digestive Disease Center and Research Institute, Department of Internal Medicine, Bucheon, Korea, Republic of, 2Asan Medical Center, University of Ulsan College of Medicine, Gastroenterology, Seoul, Korea, Republic of, 3University of Ulsan College of Medicine, Biochemistry and Molecular Biology, Seoul, Korea, Republic of, 4Kyung Hee University Hospital at Gang Dong, Kyung Hee University School of Medicine, Internal Medicine, Seoul, Korea, Republic of

P703. A prospective study on Clostridium difficile infection, toxino type and antibiotic sensitivity in inflammatory bowel disease
Authors:

M. Martinato1, A.R. Grillo1, R. D'Incà1, M. Scarpa2, R. Caccaro1, G.C. Sturniolo1, I. Castagluoilo1, 1Università degli Studi di Padova, Padova, Italy, 2Istituto Oncologico Veneto, Italy